Parainfluenza Virus type 3 Native Protein

Product Discontinued

Parainfluenza Virus type 3 Native Protein Summary

• Description: Native parainfluenza virus 3, C243 strain, cultured in Vero cells.
  
  

  Source:Virus

• Preparation Method: Optimally infected monolayers are harvested, disrupted by sonication and subjected to low speed centrifugation. The clarified cell lysate is pooled with supernatant from the infected culture and concentrated using crossflow ultrafiltration with a 30,000 m
• Protein/Peptide Type: Native Protein

Applications/Dilutions

• Dilutions:
  • ELISA

Packaging, Storage & Formulations

• Storage: Store at -80C. Avoid freeze-thaw cycles.
• Buffer: Tissue Culture Media
• Concentration: 1.58 mg/ml

Background

Human parainfluenza viruses (HPIV) were first discovered in the late 1950s. HPIV is genetically and antigenically divided into types 1 to 4. HPIV 1 to HPIV 3 are major causes of lower respiratory infections in infants, young children, the immunocompromised, the chronically ill, and the elderly. Each subtype can cause somewhat unique clinical diseases in different hosts. HPIV are enveloped and of medium size (150 to 250 nm), and their RNA genome is in the negative sense. These viruses belong to the Paramyxoviridae family, one of the largest and most rapidly growing groups of viruses causing significant human and veterinary disease. HPIV are closely related to recently discovered megamyxoviruses (Hendra and Nipah viruses) and metapneumovirus.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.